Therapeutic advances in Huntington's Disease

@article{Shannon2015TherapeuticAI,
  title={Therapeutic advances in Huntington's Disease},
  author={Kathleen M. Shannon and Avram Fraint},
  journal={Movement Disorders},
  year={2015},
  volume={30}
}
Huntington's disease is a rare hereditary degenerative disease with a wide variety of symptoms that encompass movement, cognition, and behavior. The genetic mutation that causes the disease has been known for more than 20 y, and animal models have illuminated a host of intracellular derangements that occur downstream of protein translation. A number of clinical trials targeting these metabolic consequences have failed to produce a single effective therapy, although clinical trials continue. New… 
Investigational agents for the management of Huntington’s disease
  • T. Müller
  • Medicine, Biology
    Expert opinion on investigational drugs
  • 2017
TLDR
There are promising, safe and well tolerated compounds for amelioration of motor and neuropsychiatric symptoms, but their efficacy still needs to be proven in clinical trials.
Therapy development in Huntington disease: From current strategies to emerging opportunities
TLDR
Given the depth and breadth of current HD drug development efforts, there is reason to believe that disease‐modifying therapies for HD will emerge, and this achievement will have profound implications for the entire neurotherapeutics field.
Huntington’s Disease
TLDR
Treatment is based largely on lifestyle interventions, supportive management, and symptomatic treatment, and particular research interest is devoted to the identification of biomarkers that would enable evaluation of the therapies before the clinical onset of the disease.
The P42 peptide and Peptide-based therapies for Huntington’s disease
TLDR
This review focused on a 23aa peptide P42, which is a part of the Htt protein, expected to work principally by preventing the abnormal Httprotein from sticking together, thereby preventing pathological consequences of aggregation and improving the symptoms of the disease.
Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities
TLDR
New insights are discussed into the molecular pathogenesis of Huntington disease and future therapeutic strategies, including the modulation of DNA repair and targeting the DNA mutation itself are discussed.
Huntington’s Disease-A Review
Huntington’s disease is an autosomal dominant disorder which usually begins in mid-life and is characterized by a progression of psychological change and dementia. Huntington’s disease consists of a
Sirtuins as Modifiers of Huntington's Disease (HD) Pathology.
  • Sin Hui Neo, B. Tang
  • Biology, Medicine
    Progress in molecular biology and translational science
  • 2018
A Review on Role of Zebrafish in Huntington’s Disease
TLDR
The role of the zebrafish in the Huntington’s disease is highlighted as its utility in the study of neurological disease and role in improving screening methods makes the treatment and therapies more productive.
Progress in developing transgenic monkey model for Huntington’s disease
TLDR
The progress in the development of the transgenic HD monkey model and the opportunities for advancing HD preclinical research are summarized.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 100 REFERENCES
Targets for future clinical trials in Huntington's disease: What's in the pipeline?
  • E. Wild, S. Tabrizi
  • Biology
    Movement disorders : official journal of the Movement Disorder Society
  • 2014
TLDR
It is concluded that many exciting therapeutics are progressing through the development pipeline, and combining a better understanding of HD biology in human patients, with concerted medicinal chemistry efforts, will be crucial for bringing about an era of effective therapies.
Symptomatic treatment of Huntington disease
Dopamine and Glutamate in Huntington's Disease: A Balancing Act
TLDR
Significant evidence indicates that glutamate and dopamine neurotransmission is affected in HD, compromising the fine balance in which DA modulates glutamate‐induced excitation in the basal ganglia and cortex.
A Monoclonal Antibody TrkB Receptor Agonist as a Potential Therapeutic for Huntington’s Disease
TLDR
The evaluation of TrkB antibodies and a panel of reported small molecule TrkB agonists are reported and the best candidate is identified, from those tested, for in vivo proof of concept studies in transgenic HD models.
Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease.
TLDR
This study examines the merits of administering a recombinant adeno-associated viral vector designed to deliver small interfering RNA (siRNA) that targets the degradation of the Htt transcript to lower Htt levels and correct the behavioral, biochemical, and neuropathological deficits shown to be associated with the YAC128 mouse model of HD.
Current therapeutic options for Huntington's disease: Good clinical practice versus evidence‐based approaches?
  • A. Killoran, K. Biglan
  • Medicine, Psychology
    Movement disorders : official journal of the Movement Disorder Society
  • 2014
TLDR
The limited evidence available and current expert opinion on medical treatment of the dominant motor, psychiatric, and cognitive features of HD are discussed, and no known effective treatment is available for cognitive dysfunction in HD.
Bilateral Globus Pallidus Stimulation in Westphal Variant of Huntington Disease
TLDR
The pathophysiologic basis of these clinical manifestations apparently resides on a pronounced degeneration of the direct monosynaptic inhibitory striato-pallidal projection (the so-called “direct” pathway), which ultimately results in increased inhibition of the ventrolateral thalamus.
Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease.
TLDR
It is found that chronic administration of 7, 8-DHF or 4'-DMA-7,8-D HF significantly improved motor deficits, ameliorated brain atrophy and extended survival in these N171-82Q HD mice, and suggest that small-molecule TrkB agonists that penetrate the brain have high potential to be further tested in clinical trials of HD.
The role of oxidative stress in Huntington's disease: are antioxidants good therapeutic candidates?
TLDR
An overview of the preclinical and clinical studies that have indicated a link between oxidative stress, neurodegeneration, and cell death in HD is presented, highlighting the evidence for the use of antioxidants including essential fatty acids, coenzyme Q10, and creatine, as potential therapeutic strategies for the treatment of this devastating Neurodegenerative disorder.
...
1
2
3
4
5
...